This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zeelenberg, I. S. Articles by Théry, C. Search for Related Content PubMed PubMed Citation Articles by Zeelenberg, I. S. Articles by Théry, C.

Targeting Tumor Antigens to Secreted Membrane Vesicles In vivo Induces Efficient Antitumor Immune Responses

¹ Institut National de la Santé et de la Recherche Médicale U653 and ² Section Recherche, Institut Curie; ³ Institut National de la Santé et de la Recherche Médicale U543, Hôpital Pitié-Salpêtrière, Paris, France; and ⁴ ExoThera LLC, Menlo Park, California

Requests for reprints: Clotilde Théry, Institut National de la Santé et de la Recherche Médicale U653, Institut Curie, 26 rue d'Ulm, 75005 Paris, France. Phone: 33-1-42-34-67-16; E-mail: clotilde.thery{at}curie.fr.

Key Words: immune response • antigen presentation • exosomes • cytotoxic T cells • DNA vaccination

Expression of non-self antigens by tumors can induce activation of T cells in vivo, although this activation can lead to either immunity or tolerance. CD8⁺ T-cell activation can be direct (if the tumor expresses MHC class I molecules) or indirect (after the capture and cross-presentation of tumor antigens by dendritic cells). The modes of tumor antigen capture by dendritic cells in vivo remain unclear. Here we examine the immunogenicity of the same model antigen secreted by live tumors either in association with membrane vesicles (exosomes) or as a soluble protein. We have artificially addressed the antigen to secreted vesicles by coupling it to the factor VIII–like C1C2 domain of milk fat globule epidermal growth factor-factor VIII (MFG-E8)/lactadherin. We show that murine fibrosarcoma tumor cells that secrete vesicle-bound antigen grow slower than tumors that secrete soluble antigen in immunocompetent, but not in immunodeficient, host mice. This growth difference is due to the induction of a more potent antigen-specific antitumor immune response in vivo by the vesicle-bound than by the soluble antigen. Finally, in vivo secretion of the vesicle-bound antigen either by tumors or by vaccination with naked DNA protects against soluble antigen-secreting tumors. We conclude that the mode of secretion can determine the immunogenicity of tumor antigens and that manipulation of the mode of antigen secretion may be used to optimize antitumor vaccination protocols. [Cancer Res 2008;68(4):1228–35]

This article has been cited by other articles:

				L. Klotz, S. Hucke, D. Thimm, S. Classen, A. Gaarz, J. Schultze, F. Edenhofer, C. Kurts, T. Klockgether, A. Limmer, et al. Increased Antigen Cross-Presentation but Impaired Cross-Priming after Activation of Peroxisome Proliferator-Activated Receptor {gamma} Is Mediated by Up-Regulation of B7H1 J. Immunol., July 1, 2009; 183(1): 129 - 136. [Abstract] [Full Text] [PDF]